<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>STRATTERA- atomoxetine hydrochlorideÂ capsuleÂ </strong><br>Carilion Materials Management<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use STRATTERA safely and effectively. See full prescribing information for STRATTERA. STRATTERA (atomoxetine) CAPSULES for Oral Use Initial U.S. Approval:  2002
        <br><span class="Sup">Â®</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">SUICIDAL IDEATION</span> IN CHILDREN AND ADOLESCENTS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li>
<span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in children or adolescents</span><span class="Bold">( )
                                            <a href="#s22">5.1</a></span>
</li>
<li>
<span class="Bold">No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in clinical trials</span><span class="Bold">( )
                                            <a href="#s22">5.1</a></span>
</li>
<li>
<span class="Bold">Patients started on therapy should be monitored closely</span><span class="Bold">( )
                                            <a href="#s22">5.1</a></span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" width="78.550%">
<col align="left" width="21.450%">
<tbody class="Headless">
<tr>
<td align="left" valign="top"><span class="Bold">Contraindications:</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â Severe <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> ( )
                                                <a href="#s20b">4.5</a>
</td>
<td align="left" valign="top">08/2013</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Warnings and Precautions:</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â Effects on Blood Pressure and Heart Rate ( )
                                                <a href="#s29">5.4</a>
</td>
<td align="left" valign="top">08/2013</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive Behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span> ( )
                                                <a href="#s33">5.7</a>
</td>
<td align="left" valign="top">08/2013</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">SUICIDAL IDEATION</span> IN CHILDREN AND ADOLESCENTS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li>
<span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in children or adolescents</span><span class="Bold">( )
                                            <a href="#s22">5.1</a></span>
</li>
<li>
<span class="Bold">No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in clinical trials</span><span class="Bold">( )
                                            <a href="#s22">5.1</a></span>
</li>
<li>
<span class="Bold">Patients started on therapy should be monitored closely</span><span class="Bold">( )
                                            <a href="#s22">5.1</a></span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">STRATTERA is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>). ( )
                                    <span class="Sup">Â®</span><a href="#s4">1.1</a> </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Initial, Target and Maximum Daily Dose ( )
                                    <a href="#s8">2.1</a> </p>
<p class="Highlighta">(Acute and Maintenance/Extended Treatment) </p>
<table width="100%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body Weight</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Initial Daily Dose</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Target Total Daily Dose</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Maximum Total Daily Dose</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="Highlighta">Children and adolescents up to 70Â kg
                                                    <br> </p></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="Highlighta">0.5Â mg/kg
                                                    <br> </p></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="Highlighta">1.2Â mg/kg
                                                    <br> </p></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="Highlighta">1.4Â mg/kg
                                                    <br> </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="Highlighta">Children and adolescents over 70Â kg and adults
                                                    <br> </p></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="Highlighta">40Â mg
                                                    <br> </p></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="Highlighta">80Â mg
                                                    <br> </p></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="Highlighta">100Â mg
                                                    <br> </p></td>
</tr>
</tbody>
</table>
<p class="Highlighta">Dosing adjustment â€” <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( , )
                                    <a href="#s13">2.4</a><a href="#s91">12.3</a> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of atomoxetine. ( , , )
                                    <a href="#s16">3</a><a href="#s87">11</a><a href="#s104">16</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to atomoxetine or other constituents of product. ( )
                                        <a href="#s18">4.1</a>
</li>
<li>STRATTERA use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. ( , )
                                        <a href="#s19">4.2</a><a href="#s54">7.1</a>
</li>
<li>Narrow Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>. ( )
                                        <a href="#s20">4.3</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span> or history of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. ( )
                                        <a href="#s20a">4.4</a>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> that might deteriorate with clinically important increases in HR and BP. ( )
                                        <a href="#s20b">4.5</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal Ideation</span> â€“ Monitor for suicidality, clinical worsening, and unusual changes in behavior. ( )
                                        <a href="#s22">5.1</a>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span> â€“ Should be discontinued and not restarted in patients with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. ( )
                                        <a href="#s23">5.2</a>
</li>
<li>Serious Cardiovascular Events â€“ <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported in association with atomoxetine treatment. Patients should have a careful history and physical exam to assess for presence of cardiovascular disease. STRATTERA generally should not be used in children or adolescents with known serious structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to its noradrenergic effects. Consideration should be given to not using STRATTERA in adults with clinically significant cardiac abnormalities. ( )
                                        <a href="#s24">5.3</a>
</li>
<li>Emergent Cardiovascular Symptoms â€“ Patients should undergo prompt cardiac evaluation. ( )
                                        <a href="#s24">5.3</a>
</li>
<li>Effects on Blood Pressure and Heart Rate â€“ Increase in blood pressure and heart rate; orthostasis and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may occur. Use with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, or cardiovascular or cerebrovascular disease. ( )
                                        <a href="#s29">5.4</a>
</li>
<li>Emergent <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> Symptoms â€“ Consider discontinuing treatment if such new symptoms occur. ( )
                                        <a href="#s31">5.5</a>
</li>
<li>Bipolar Disorder â€“ Screen patients to avoid possible induction of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>. ( )
                                        <a href="#s32">5.6</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> should be monitored. ( )
                                        <a href="#s33">5.7</a>
</li>
<li>Possible <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. ( )
                                        <a href="#s34">5.8</a>
</li>
<li>Effects on Urine Outflow â€“ <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary hesitancy</span> and retention may occur. ( )
                                        <a href="#s35">5.9</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> â€“ Prompt medical attention is required in the event of suspected <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>. ( , )
                                        <a href="#s36">5.10</a><a href="#s112">17.5</a>
</li>
<li>Growth â€“ Height and weight should be monitored in pediatric patients. ( )
                                        <a href="#s37">5.11</a>
</li>
<li>Concomitant Use of Potent CYP2D6 Inhibitors or Use in patients known to be CYP2D6 PMs â€“ Dose adjustment of STRATTERA may be necessary. ( )
                                        <a href="#s40">5.13</a>
</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Most common adverse reactions (â‰¥5% and at least twice the incidence of placebo patients)</span> </p>
<ul class="Disc">
<li>Child and Adolescent Clinical Trials â€“ <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. ( )
                                        <a href="#s42">6.1</a>
</li>
<li>Adult Clinical Trials â€“ <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, and <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span>. ( )
                                        <a href="#s42">6.1</a>
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Monoamine Oxidase Inhibitors. ( , )
                                        <a href="#s19">4.2</a><a href="#s54">7.1</a>
</li>
<li>CYP2D6 Inhibitors - Concomitant use may increase atomoxetine steady-state plasma concentrations in EMs. ( )
                                        <a href="#s55">7.2</a>
</li>
<li>Antihypertensive Drugs and Pressor Agents - Possible effects on blood pressure. ( )
                                        <a href="#s56">7.3</a>
</li>
<li>Albuterol (or other beta agonists) - Action of albuterol on cardiovascular system can be potentiated. ( )
                                        <span class="Sub">2</span><a href="#s57">7.4</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy/Lactation - Pregnant or nursing women should not use unless potential benefit justifies potential risk to fetus or infant. ( , )
                                        <a href="#s66">8.1</a><a href="#s69">8.3</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> - Increased exposure (AUC) to atomoxetine than with normal subjects in EM subjects with moderate (Child-Pugh Class B) (2-fold increase) and severe (Child-Pugh Class C) (4-fold increase). ( )
                                        <a href="#s72">8.6</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> - Higher systemic exposure to atomoxetine than healthy subjects for EM subjects with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> - no difference when exposure corrected for mg/kg dose. ( )
                                        <a href="#s73">8.7</a>
</li>
<li>Patients with Concomitant Illness - Does not worsen <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and comorbid Tourette's Disorder. ( )
                                        <a href="#s76">8.10</a>
</li>
<li>Patients with Concomitant Illness â€“ Does not worsen <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and comorbid <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">Anxiety Disorders</span>. ( )
                                        <a href="#s76">8.10</a>
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">SUICIDAL IDEATION</span> IN CHILDREN AND ADOLESCENTS</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Diagnostic Considerations</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Need for Comprehensive Treatment Program</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Acute Treatment</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Maintenance/Extended Treatment</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 General Dosing Information</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosing in Specific Populations</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Monoamine Oxidase Inhibitors (MAOI)</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Narrow Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-4.4" class="toc">4.4 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></a></h2>
<h2><a href="#section-4.5" class="toc">4.5 Severe <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal Ideation</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Serious Cardiovascular Events</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Effects on Blood Pressure and Heart Rate</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Emergence of New <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> Symptoms</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Screening Patients for Bipolar Disorder</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive Behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Allergic Events</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Effects on Urine Outflow from the Bladder</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Effects on Growth</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Laboratory Tests</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Concomitant Use of Potent CYP2D6 Inhibitors or Use in patients who are known to be CYP2D6 PMs</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Spontaneous Reports</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effect of CYP2D6 Inhibitors on Atomoxetine</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Antihypertensive Drugs and Pressor Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Albuterol</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Effect of Atomoxetine on P450 Enzymes</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Alcohol</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Methylphenidate</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Drugs Highly Bound to Plasma Protein</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Drugs that Affect GastricÂ pH</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Gender</a></h2>
<h2><a href="#section-8.9" class="toc">8.9 Ethnic Origin</a></h2>
<h2><a href="#section-8.10" class="toc">8.10 Patients with Concomitant Illness</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> studies in Children and Adolescents</a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> studies in Adults</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 General Information</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span></a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Ocular Irritant</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Drug-Drug Interaction</a></h2>
<h2><a href="#section-16.8" class="toc">17.8 Pregnancy</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Food</a></h2>
<h2><a href="#section-16.10" class="toc">17.10 Missed Dose</a></h2>
<h2><a href="#section-16.11" class="toc">17.11 Interference with Psychomotor Performance</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">SUICIDAL IDEATION</span> IN CHILDREN AND ADOLESCENTS</h1>
<p class="First"><span class="Bold">STRATTERA (atomoxetine) increased the risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in short-term studies in children or adolescents with Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>). Anyone considering the use of STRATTERA in a child or adolescent must balance this risk with the clinical need. Co-morbidities occurring with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> may be associated with an increase in the risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and/or behavior. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. STRATTERA is approved for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> in pediatric and adult patients. STRATTERA is not approved for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>.</span></p>
<p><span class="Bold">Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of STRATTERA in children and adolescents (a total of 12 trials involving over 2200 patients, including 11 trials in <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and 1 trial in <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>) have revealed a greater risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> early during treatment in those receiving STRATTERA compared to placebo. The average risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in patients receiving STRATTERA was 0.4% (5/1357 patients), compared to none in placebo-treated patients (851 patients). No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in these trials .
                                <span class="Bold Italics">[see Warnings and Precautions ( )]
                                    <a href="#s22">5.1</a></span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>)</h2>
<p class="First">STRATTERA is indicated for the treatment of Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>).</p>
<p>The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) .
                                    <span class="Italics">[see Clinical Studies ( )]
                                        <a href="#s99">14</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Diagnostic Considerations</h2>
<p class="First">A diagnosis of ADHDÂ (DSM-IV) implies the presence of <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>-impulsive or inattentive symptoms that cause impairment and that were present before ageÂ 7Â years. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g.,Â in social, academic, or occupational functioning, and must be present in 2Â or more settings, e.g.,Â school (or work) and at home. The symptoms must not be better accounted for by another <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">mental disorder</span>.</p>
<p>The specific etiology of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM-IV characteristics.</p>
<p>For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6Â months: lack of attention to details/careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactive</span>-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming, leaving seat, inappropriate running/climbing, difficulty with quiet activities, â€œon the go,â€? excessive talking, blurting answers, can't wait turn, intrusive. For a Combined Type diagnosis, both inattentive and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>-impulsive criteria must be met.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Need for Comprehensive Treatment Program</h2>
<p class="First">STRATTERA is indicated as an integral part of a total treatment program for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Acute Treatment</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.1.1"></a><p></p>
<p class="First">Â â€” STRATTERA should be initiated at a total daily dose of approximately 0.5Â mg/kg and increased after a minimum of 3Â days to a target total daily dose of approximately 1.2Â mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2Â mg/kg/day .
                                            <span class="Underline">Dosing of children and adolescents up to 70Â kg body weight</span><span class="Italics">[seeÂ Clinical Studies ( )]
                                                <a href="#s99">14</a></span></p>
<p>The total daily dose in children and adolescents should not exceed 1.4Â mg/kg or 100Â mg, whichever is less.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.1.2"></a><p></p>
<p class="First">Â â€” STRATTERA should be initiated at a total daily dose of 40Â mg and increased after a minimum of 3Â days to a target total daily dose of approximately 80Â mg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After 2Â toÂ 4Â additional weeks, the dose may be increased to a maximum of 100Â mg in patients who have not achieved an optimal response. There are no data that support increased effectiveness at higher doses .
                                            <span class="Underline">Dosing of children and adolescents over 70Â kg body weight and adults</span><span class="Italics">[seeÂ Clinical Studies ( )]
                                                <a href="#s99">14</a></span></p>
<p>The maximum recommended total daily dose in children and adolescents over 70Â kg and adults is 100Â mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Maintenance/Extended Treatment</h2>
<p class="First">It is generally agreed that pharmacological treatment of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> may be needed for extended periods. The benefit of maintaining pediatric patients (ages 6-15 years) with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> on STRATTERA after achieving a response in a dose range of 1.2 to 1.8 mg/kg/day was demonstrated in a controlled trial. Patients assigned to STRATTERA in the maintenance phase were generally continued on the same dose used to achieve a response in the open label phase. The physician who elects to use STRATTERA for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient .
                                    <span class="Italics">[seeÂ Clinical Studies ( )]
                                        <a href="#s100">14.1</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.3"></a><p></p>
<h2>2.3 General Dosing Information</h2>
<p class="First">STRATTERA may be taken with or without food.</p>
<p>STRATTERA can be discontinued without being tapered.</p>
<p>STRATTERA capsules are not intended to be opened, they should be taken whole .
                                    <span class="Italics">[see Patient Counseling Information ( )]
                                        <a href="#s113">17.6</a></span></p>
<p>The safety of single doses over 120Â mg and total daily doses above 150Â mg have not been systematically evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosing in Specific Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.4.1"></a><p></p>
<p class="First">â€” For those <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> patients who have <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (HI), dosage adjustment is recommended as follows:Â For patients with moderate HIÂ (Child-Pugh ClassÂ B), initial and target doses should be reduced to 50%Â of the normal dose (for patients without HI). For patients with severe HIÂ (Child-Pugh ClassÂ C), initial dose and target doses should be reduced toÂ 25% of normal .
                                            <span class="Underline">Dosing adjustment for hepatically impaired patients</span><span class="Italics">[see Use In Specific Populations ( )]
                                                <a href="#s72">8.6</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.4.2"></a><p></p>
<p class="First">â€” In children and adolescents up to 70Â kg body weight administered strong CYP2D6 inhibitors, e.g.,Â paroxetine, fluoxetine, and quinidine, or in patients who are known to be CYP2D6 PMs, STRATTERA should be initiated at 0.5Â mg/kg/day and only increased to the usual target dose of 1.2Â mg/kg/day if symptoms fail to improve after 4Â weeks and the initial dose is well tolerated.
                                            <span class="Underline">Dosing adjustment for use with a strong CYP2D6 inhibitor or in patients who are known to be CYP2D6 PMs</span></p>
<p>In children and adolescents over 70Â kg body weight and adults administered strong CYP2D6 inhibitors, e.g.,Â paroxetine, fluoxetine, and quinidine, STRATTERA should be initiated at 40Â mg/day and only increased to the usual target dose of 80Â mg/day if symptoms fail to improve after 4Â weeks and the initial dose is well tolerated.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s16"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each capsule contains atomoxetine HCl equivalent to 10Â mg (Opaque White, Opaque White), 18Â mg (Gold, Opaque White), 25Â mg (Opaque Blue, Opaque White), 40Â mg (Opaque Blue, Opaque Blue), 60Â mg (Opaque Blue, Gold), 80Â mg (Opaque Brown, Opaque White), or 100Â mg (Opaque Brown, Opaque Brown) of atomoxetine.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s17"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">STRATTERA is contraindicated in patients known to be hypersensitive to atomoxetine or other constituents of the product .
                                    <span class="Italics">[seeÂ Warnings and Precautions ( )]
                                        <a href="#s34">5.8</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Monoamine Oxidase Inhibitors (MAOI)</h2>
<p class="First">STRATTERA should not be taken with an MAOI, or within 2Â weeks after discontinuing an MAOI. Treatment with an MAOI should not be initiated within 2Â weeks after discontinuing STRATTERA. With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>) when taken in combination with an MAOI. Some cases presented with features resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Such reactions may occur when these drugs are given concurrently or in close proximity .
                                    <span class="Italics">[see Drug Interactions ( )]
                                        <a href="#s54">7.1</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Narrow Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">In clinical trials, STRATTERA use was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> and therefore its use is not recommended in patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20a"></a><a name="section-4.4"></a><p></p>
<h2>4.4 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></h2>
<p class="First">Serious reactions, including elevated blood pressure and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span>, have been reported in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or a history of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> who received STRATTERA. Therefore, STRATTERA should not be taken by patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or a history of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20b"></a><a name="section-4.5"></a><p></p>
<h2>4.5 Severe <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First" style="border-left:1px solid;">STRATTERA should not be used in patients with severe cardiac or <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorders</span> whose condition would be expected to deteriorate if they experience increases in blood pressure or heart rate that could be clinically important (for example, 15 to 20 mm Hg in blood pressure or 20 beats per minute in heart rate). .
                                    <span class="XmChange"></span><span class="Italics">[See Warnings and Precautions ( )]
                                        <a href="#s29">5.4</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s21"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal Ideation</span></h2>
<p class="First">STRATTERA increased the risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in short-term studies in children and adolescents with Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>). Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of STRATTERA in children and adolescents have revealed a greater risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> early during treatment in those receiving STRATTERA. There were a total of 12 trials (11 in <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and 1 in <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>) involving over 2200 patients (including 1357 patients receiving STRATTERA and 851 receiving placebo). The average risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in patients receiving STRATTERA was 0.4% (5/1357 patients), compared to none in placebo-treated patients. There was 1 <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> among these approximately 2200 patients, occurring in a patient treated with STRATTERA. All reactions occurred in children 12 years of age or younger. All reactions occurred during the first month of treatment. It is unknown whether the risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> in pediatric patients extends to longer-term use. A similar analysis in adult patients treated with STRATTERA for either <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> or major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) did not reveal an increased risk of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> or behavior in association with the use of STRATTERA.
                                    <span class="Bold">No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in these trials.</span></p>
<p><span class="Bold">All pediatric patients being treated with STRATTERA should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms have been reported with STRATTERA: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>. Although a causal link between the emergence of such symptoms and the emergence of suicidal impulses has not been established, there is a concern that such symptoms may represent precursors to emerging suicidality. Thus, patients being treated with STRATTERA should be observed for the emergence of such symptoms.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who are experiencing emergent suicidality or symptoms that might be precursors to emerging suicidality, especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms.</p>
<p><span class="Bold">Families and caregivers of pediatric patients being treated with STRATTERA should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></h2>
<p class="First">Postmarketing reports indicate that STRATTERA can cause severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. Although no evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> that were considered probably or possibly related to STRATTERA use in postmarketing experience. Rare cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> have also been reported, including a case that resulted in a liver transplant. Because of probable underreporting, it is impossible to provide an accurate estimate of the true incidence of these reactions. Reported cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occurred within 120 days of initiation of atomoxetine in the majority of cases and some patients presented with markedly elevated liver enzymes [&gt;20 X upper limit of normal (ULN)], and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with significantly elevated bilirubin levels (&gt;2 X ULN), followed by recovery upon atomoxetine discontinuation. In one patient, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, manifested by elevated hepatic enzymes up to 40Â X ULN and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with bilirubin up to 12Â X ULN, recurred upon rechallenge, and was followed by recovery upon drug discontinuation, providing evidence that STRATTERA likely caused the <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. Such reactions may occur several months after therapy is started, but laboratory abnormalities may continue to worsen for several weeks after drug is stopped. The patient described above recovered from his <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, and did not require a liver transplant.</p>
<p>Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, dark urine, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or unexplained â€œflu likeâ€? symptoms) .
                                    <span class="Bold">STRATTERA should be discontinued in patients with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, and should not be restarted.</span><span class="Italics">[see Warnings and Precautions ( ); Patient Counseling Information ( )]
                                        <a href="#s38">5.12</a><a href="#s110">17.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Serious Cardiovascular Events</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden Death</span> and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.3.2"></a><p></p>
<p class="First">â€” <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span> has been reported in association with atomoxetine treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, atomoxetine generally should not be used in children or adolescents with known serious structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the noradrenergic effects of atomoxetine.
                                            <span class="Underline">Children and Adolescents</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.3.3"></a><p></p>
<p class="First">â€” <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden deaths</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported in adults taking atomoxetine at usual doses for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>. Although the role of atomoxetine in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, or other serious cardiac problems. Consideration should be given to not treating adults with clinically significant cardiac abnormalities.
                                            <span class="Underline">Adults</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-5.3.4"></a><p></p>
<p class="First"><span class="Bold">Assessing Cardiovascular Status in Patients being Treated with Atomoxetine</span></p>
<p>Children, adolescents, or adults who are being considered for treatment with atomoxetine should have a careful history (including assessment for a family history of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Effects on Blood Pressure and Heart Rate</h2>
<p class="First" style="border-left:1px solid;">STRATTERA should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorders</span> whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate . Pulse and blood pressure should be measured at baseline, following STRATTERA dose increases, and periodically while on therapy to detect possible clinically important increases.
                                    <span class="XmChange"></span><span class="Italics">[see Contraindications ( )]
                                        <a href="#s20b">4.5</a></span></p>
<p>The following table provides short-term, placebo-controlled clinical trial data for the proportions of patients having an increase in: diastolic blood pressure â‰¥15 mm Hg; systolic blood pressure â‰¥20 mm Hg; heart rate greater than or equal to 20 bpm, in both the pediatric and adult populations ( ).
                                    <span class="Italics">see</span><a href="#t1">Table 1</a></p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1
                                        <span class="Sup">a</span></span></caption>
<col align="left" width="12.000%">
<col align="left" width="10.323%">
<col align="left" width="10.323%">
<col align="left" width="10.323%">
<col align="left" width="10.243%">
<col align="left" width="10.323%">
<col align="left" width="10.323%">
<col align="left" width="10.323%">
<col align="left" width="10.243%">
<tfoot><tr class="First Last"><td align="left" colspan="9" valign="top">
<p class="First Footnote">Abbreviations: bpm=beats per minute; DBP=diastolic blood pressure; HR=heart rate; mm Hg=millimeters mercury; SBP=systolic blood pressure.
                                                    <span class="Sup">a</span></p>
<p class="Footnote">Proportion of patients meeting threshold at any one time during clinical trial.
                                                    <span class="Sup">b</span></p>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Pediatric Acute Placebo-Controlled
                                                    <br></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Adult Acute Placebo-Controlled
                                                    <br></span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Maximum
                                                    <span class="Sup">b</span></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Endpoint</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Maximum
                                                    <span class="Sup">b</span></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Endpoint</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Atomoxetine</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Atomoxetine</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Atomoxetine</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Atomoxetine</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">DBP (â‰¥15 mm Hg)
                                                <br>
</td>
<td class="Botrule Rrule" align="center" valign="middle">21.5</td>
<td class="Botrule Rrule" align="center" valign="middle">14.1</td>
<td class="Botrule Rrule" align="center" valign="middle">9.3</td>
<td class="Botrule Rrule" align="center" valign="middle">4.8</td>
<td class="Botrule Rrule" align="center" valign="middle">12.6</td>
<td class="Botrule Rrule" align="center" valign="middle">8.7</td>
<td class="Botrule Rrule" align="center" valign="middle">4.8</td>
<td class="Botrule Rrule" align="center" valign="middle">3.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">SBP (â‰¥20 mm Hg)
                                                <br>
</td>
<td class="Botrule Rrule" align="center" valign="middle">12.5</td>
<td class="Botrule Rrule" align="center" valign="middle">8.7</td>
<td class="Botrule Rrule" align="center" valign="middle">4.9</td>
<td class="Botrule Rrule" align="center" valign="middle">3.3</td>
<td class="Botrule Rrule" align="center" valign="middle">12.4</td>
<td class="Botrule Rrule" align="center" valign="middle">7.8</td>
<td class="Botrule Rrule" align="center" valign="middle">4.2</td>
<td class="Botrule Rrule" align="center" valign="middle">3.2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">HR (â‰¥20 bpm)
                                                <br>
</td>
<td class="Botrule Rrule" align="center" valign="middle">23.4</td>
<td class="Botrule Rrule" align="center" valign="middle">11.5</td>
<td class="Botrule Rrule" align="center" valign="middle">12.2</td>
<td class="Botrule Rrule" align="center" valign="middle">3.8</td>
<td class="Botrule Rrule" align="center" valign="middle">22.4</td>
<td class="Botrule Rrule" align="center" valign="middle">8.3</td>
<td class="Botrule Rrule" align="center" valign="middle">10.2</td>
<td class="Botrule Rrule" align="center" valign="middle">2.0</td>
</tr>
</tbody>
</table>
<p>In placebo-controlled registration studies involving pediatric patients, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> was identified as an adverse event for 0.3% (5/1597) of these STRATTERA patients compared with 0% (0/934) of placebo patients. The mean heart rate increase in extensive metabolizer (EM) patients was 5.0 beats/minute, and in poor metabolizer (PM) patients 9.4 beats/minute.</p>
<p>In adult clinical trials where EM/PM status was available, the mean heart rate increase in PM patients was significantly higher than in EM patients (11Â beats/minute versus 7.5Â beats/minute). The heart rate effects could be clinically important in some PM patients.</p>
<p>In placebo-controlled registration studies involving adult patients, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> was identified as an adverse event for 1.5% (8/540) of STRATTERA patients compared with 0.5% (2/402) of placebo patients.</p>
<p>In adult clinical trials where EM/PM status was available, the mean change from baseline in diastolic blood pressure in PM patients was higher than in EM patients (4.21 versus 2.13 mm Hg) as was the mean change from baseline in systolic blood pressure (PM: 2.75 versus EM: 2.40Â mmÂ Hg). The blood pressure effects could be clinically important in some PM patients.</p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been reported in patients taking STRATTERA. In child and adolescent registration studies, 0.2% (12/5596) of STRATTERA-treated patients experienced <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and 0.8% (46/5596) experienced <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. In short-term child and adolescent registration studies, 1.8% (6/340) of STRATTERA-treated patients experienced <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> compared with 0.5% (1/207) of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> was not reported during short-term child and adolescent placebo-controlled <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> registration studies. STRATTERA should be used with caution in any condition that may predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or conditions associated with abrupt heart rate or blood pressure changes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Emergence of New <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> Symptoms</h2>
<p class="First">Treatment emergent <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms, e.g., <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, delusional thinking, or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in children and adolescents without a prior history of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illness or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.2% (4 patients with reactions out of 1939 exposed to atomoxetine for several weeks at usual doses) of atomoxetine-treated patients compared to 0 out of 1056 placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Screening Patients for Bipolar Disorder</h2>
<p class="First">In general, particular care should be taken in treating <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with STRATTERA, patients with comorbid <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive Behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span></h2>
<p class="First" style="border-left:1px solid;">Patients beginning treatment for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> should be monitored for the appearance or worsening of <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>. <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> is often observed in children and adolescents with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>. In pediatric short-term controlled clinical trials, 21/1308 (1.6%) of atomoxetine patients versus 9/806 (1.1%) of placebo-treated patients spontaneously reported treatment emergent <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>-related adverse events (overall risk ratio of 1.33 [95% C.I. 0.67-2.64 â€“ not statistically significant]). In adult placebo-controlled clinical trials, 6/1697 (0.35%) of atomoxetine patients versus 4/1560 (0.26%) of placebo-treated patients spontaneously reported treatment emergent <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>-related adverse events (overall risk ratio of 1.38 [95% C.I. 0.39-4.88 â€“ not statistically significant]). Although this is not conclusive evidence that STRATTERA causes <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, these behaviors were more frequently observed in clinical trials among children, adolescents, and adults treated with STRATTERA compared to placebo.
                                    <span class="XmChange"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Allergic Events</h2>
<p class="First">Although uncommon, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, have been reported in patients taking STRATTERA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Effects on Urine Outflow from the Bladder</h2>
<p class="First">In adult <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> controlled trials, the rates of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (1.7%,Â 9/540) and <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span> (5.6%,Â 30/540) were increased among atomoxetine subjects compared with placebo subjects (0%,Â 0/402 ; 0.5%, 2/402, respectively). TwoÂ adult atomoxetine subjects and no placebo subjects discontinued from controlled clinical trials because of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. A complaint of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> or <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> should be considered potentially related to atomoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></h2>
<p class="First">Rare postmarketing cases of <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, defined as painful and nonpainful penile erection lasting more than 4 hours, have been reported for pediatric and adult patients treated with STRATTERA. The erections resolved in cases in which follow-up information was available, some following discontinuation of STRATTERA. Prompt medical attention is required in the event of suspected <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Effects on Growth</h2>
<p class="First">Data on the long-term effects of STRATTERA on growth come from open-label studies, and weight and height changes are compared to normative population data. In general, the weight and height gain of pediatric patients treated with STRATTERA lags behind that predicted by normative population data for about the first 9-12Â months of treatment. Subsequently, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> rebounds and at about 3Â years of treatment, patients treated with STRATTERA have gained 17.9Â kg on average, 0.5Â kg more than predicted by their baseline data. After about 12Â months, gain in height stabilizes, and at 3Â years, patients treated with STRATTERA have gained 19.4Â cm on average, 0.4Â cm less than predicted by their baseline data ( below).
                                    <span class="Italics">see</span><a href="#f01">FigureÂ 1</a></p>
<div class="Figure">
<a name="f01"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6a7584b5-524d-4726-86a2-1b08e422f60e&amp;name=strattera2.jpg"><p class="MultiMediaCaption">Figure 1: Mean Weight and Height Percentiles Over Time for Patients With Three Years of STRATTERA Treatment</p>
</div>
<p>This growth pattern was generally similar regardless of pubertal status at the time of treatment initiation. Patients who were pre-pubertal at the start of treatment (girlsÂ â‰¤8Â years old, boysÂ â‰¤9Â years old) gained an average of 2.1Â kg and 1.2Â cm less than predicted after threeÂ years. Patients who were pubertal (girlsÂ &gt;8Â to â‰¤13Â years old, boys &gt;9Â to â‰¤14Â years old) or late pubertal (girlsÂ &gt;13Â years old, boysÂ &gt;14Â years old) had average weight and height gains that were close to or exceeded those predicted after threeÂ years of treatment.</p>
<p>Growth followed a similar pattern in both extensive and poor metabolizersÂ (EMs, PMs). PMs treated for at least twoÂ years gained an average of 2.4Â kg and 1.1Â cm less than predicted, while EMs gained an average of 0.2Â kg and 0.4Â cm less than predicted.</p>
<p>In short-term controlled studies (up to 9Â weeks), STRATTERA-treated patients lost an average of 0.4Â kg and gained an average of 0.9Â cm, compared to a gain of 1.5Â kg and 1.1Â cm in the placebo-treated patients. In a fixed-dose controlled trial, 1.3%, 7.1%, 19.3%, and 29.1% of patients lost at least 3.5%Â of their body weight in the placebo, 0.5, 1.2, andÂ 1.8Â mg/kg/day dose groups.</p>
<p>Growth should be monitored during treatment with STRATTERA.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s38"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Laboratory Tests</h2>
<p class="First">Routine laboratory tests are not required.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-5.12.1"></a><p></p>
<p class="First">â€” Poor metabolizersÂ (PMs) of CYP2D6 have a 10-fold higher AUC and a 5-fold higher peak concentration to a given dose of STRATTERA compared with extensive metabolizersÂ (EMs). Approximately 7% of a Caucasian population are PMs. Laboratory tests are available to identify CYP2D6Â PMs. The blood levels in PMs are similar to those attained by taking strong inhibitors of CYP2D6. The higher blood levels in PMs lead to a higher rate of some adverse effects of STRATTERA .
                                            <span class="Underline">CYP2D6 metabolism</span><span class="Italics">[seeÂ Adverse Reactions ( )]
                                                <a href="#s42">6.1</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Concomitant Use of Potent CYP2D6 Inhibitors or Use in patients who are known to be CYP2D6 PMs</h2>
<p class="First">Atomoxetine is primarily metabolized by the CYP2D6Â pathway to 4-hydroxyatomoxetine. Dosage adjustment of STRATTERA may be necessary when coadministered with potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, and quinidine) or when administered to CYP2D6 PMs. .
                                    <span class="Italics">[See Dosage and Administration ( ) and Drug Interactions ( )]
                                        <a href="#s13">2.4</a><a href="#s55">7.2</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s41"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">STRATTERA was administered to 5382Â children or adolescent patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and 1007 adults with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> in clinical studies. During the <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> clinical trials, 1625 children and adolescentÂ patients were treated for longer than 1Â year and 2529 children and adolescentÂ patients were treated for over 6Â months.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Child and Adolescent Clinical Trials</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-6.1.2"></a><p></p>
<p class="First">Â â€” In acute child and adolescent placebo-controlled trials, 3.0%Â (48/1613) of atomoxetine subjects and 1.4%Â (13/945) placebo subjects discontinued for adverse reactions. For all studies, (including open-label and long-term studies), 6.3% of extensive metabolizerÂ (EM) patients and 11.2% of poor metabolizerÂ (PM) patients discontinued because of an adverse reaction. Among STRATTERA-treated patients, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (0.3%, N=5); <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (0.3%, N=5); <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> (0.2%, N=4); <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.2%, N=4); <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.2%, N=4); <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (0.2%, N=4); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (0.1%, N=2); <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (0.1%, N=2); <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span> (0.1%, N=2); and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.1%, N=2) were the reasons for discontinuation reported by more than 1Â patient.
                                            <span class="Underline">Reasons for discontinuation of treatment due to adverse reactions in child and adolescent clinical trials</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-6.1.3"></a><p></p>
<p class="First">â€” STRATTERA has not been systematically evaluated in pediatric patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder as these patients were excluded from clinical studies during the product's premarket testing. In the clinical development program, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported in 0.2% (12/5073) of children whose average age was 10 years (range 6 to 16 years). In these clinical trials, the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk among poor metabolizers was 0.3% (1/293) compared to 0.2% (11/4741) for extensive metabolizers.
                                            <span class="Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-6.1.4"></a><p></p>
<p class="First">Â â€” Commonly observed adverse reactions associated with the use of STRATTERA (incidence ofÂ 2% or greater) and not observed at an equivalent incidence among placebo-treated patients (STRATTERA incidence greater than placebo) are listed in . Results were similar in the BID and the QDÂ trial except as shown in , which shows both BID and QDÂ results for selected adverse reactions based on statistically significant Breslow-Day tests. The most commonly observed adverse reactions in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients, for either BID or QDÂ dosing) were:Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> ( Â  Â  ).
                                            <span class="Underline">Commonly observed adverse reactions in acute child and adolescent, placebo-controlled trials</span><a href="#t2">TableÂ 2</a><a href="#t3">TableÂ 3</a><span class="Italics">see</span><a href="#t2">TablesÂ 2</a><span class="Italics">and</span><a href="#t3">3</a></p>
<p>Additional data from <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> clinical trials (controlled and uncontrolled) has shown that approximately 5 to 10% of pediatric patients experienced potentially clinically important changes in heart rate (â‰¥20 beats per min) or blood pressure (â‰¥15 to 20Â mmÂ Hg) .
                                            <span class="Italics">[see Contraindications ( ) and Warnings and Precautions ( )]
                                                <a href="#s17">4</a><a href="#s21">5</a></span></p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Common Treatmentâ€“Emergent Adverse Reactions Associated with the Use of STRATTERA in Acute (up to 18 weeks) Child and Adolescent Trials</span></caption>
<col align="left" width="48.049%">
<col align="left" width="25.975%">
<col align="left" width="25.975%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">Reactions reported by at least 2% of patients treated with atomoxetine, and greater than placebo. The following reactions did not meet this criterion but were reported by more atomoxetine-treated patients than placebo-treated patients and are possibly related to atomoxetine treatment: <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakening</span> (terminal <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>), <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>. The following reactions were reported by at least 2% of patients treated with atomoxetine, and equal to or less than placebo: pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> includes the terms, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4243368" conceptname="Initial insomnia">initial insomnia</span>, <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span>). The following reaction did not meet this criterion but shows a statistically significant dose relationship: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.
                                                            <span class="Sup">a</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> includes the terms: <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>.
                                                            <span class="Sup">b</span></p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the terms: sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
                                                            <span class="Sup">c</span></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction
                                                            <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">STRATTERA (N=1597)
                                                            <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo (N=934)
                                                            <br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
                                                        <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4010337" conceptname="Unexpected therapeutic effect">Therapeutic response unexpected</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutritional Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="top">19</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
                                                        <span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Common Treatment-Emergent Adverse Reactions Associated with the Use of STRATTERA in Acute (up to 18 weeks) Child and Adolescent Trials</span></caption>
<col align="left" width="27.160%">
<col align="left" width="16.920%">
<col align="left" width="11.260%">
<col align="left" width="16.920%">
<col align="left" width="27.740%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> includes the terms: <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>.
                                                            <span class="Sup">a</span></p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> didn't meet the statistical significance on Breslow-Day test but is included in the table because of pharmacologic plausibility.
                                                            <span class="Sup">b</span></p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span> didn't meet the statistical significance on Breslow-Day test at 0.05 level but p-value was &lt;0.1 (trend).
                                                            <span class="Sup">c</span></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction from BID Trials
                                                            <br><br></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction from QD Trials
                                                            <br><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">STRATTERA (N=715)
                                                            <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo (N=434)
                                                            <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">STRATTERA (N=882)
                                                            <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo (N=500)
                                                            <br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
                                                        <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
                                                        <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span>
                                                        <span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
<p>The following adverse reactions occurred in at least 2% of child and adolescent CYP2D6 PM patients and were statistically significantly more frequent in PM patients compared with CYP2D6 EM patients: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (11% of PMs, 6% of EMs); <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span> (7% of PMs, 4% of EMs); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (7% of PMs, 4% of EMs); <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (7% of PMs, 4% of EMs); <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (5% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriation</span> (4% of PMs, 2% of EMs); <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span> (3% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (3% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (3% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakening</span> (2% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> (2% of PMs, 1% of EMs); sedation (4% of PMs, 2% of EMs).
                                            <span class="Sup">1</span></p>
<p><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>, <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>, <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>.
                                            <span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold">Adult Clinical Trials</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-6.1.6"></a><p></p>
<p class="First">Â â€” In the acute adult placebo-controlled trials, 11.3%Â (61/541) atomoxetine subjects and 3.0%Â (12/405) placebo subjects discontinued for adverse reactions. Among STRATTERA-treated patients, insomniaÂ (0.9%,Â N=5); <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.9%,Â N=5); chest painÂ (0.6%,Â N=3); <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (0.6%,Â N=3); <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (0.4%,Â N=2); <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (0.4%,Â N=2); <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span> (0.4%,Â N=2); <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> (0.4%,Â N=2); <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> (0.4%,Â N=2); and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (0.4%,Â N=2) were the reasons for discontinuation reported by more than 1Â patient.
                                            <span class="Underline">Reasons for discontinuation of treatment due to adverse reactions in acute adult placebo-controlled trials</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-6.1.7"></a><p></p>
<p class="First">â€” STRATTERA has not been systematically evaluated in adult patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder as these patients were excluded from clinical studies during the product's premarket testing. In the clinical development program, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported on 0.1% (1/748) of adult patients. In these clinical trials, no poor metabolizers (0/43) reported <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> compared to 0.1% (1/705) for extensive metabolizers.
                                            <span class="Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-6.1.8"></a><p></p>
<p class="First">â€” Commonly observed adverse reactions associated with the use of STRATTERA (incidence of 2% or greater) and not observed at an equivalent incidence among placebo-treated patients (STRATTERA incidence greater than placebo) are listed in . The most commonly observed adverse reactions in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients) were:Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, and <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span> ( ).
                                            <span class="Underline">Commonly observed adverse reactions in acute adult placebo-controlled trials</span><a href="#t4">TableÂ 4</a><span class="Italics">see</span><a href="#t4">Table 4</a></p>
<p>Additional data from <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> clinical trials (controlled and uncontrolled) has shown that approximately 5 to 10% of adult patients experienced potentially clinically important changes in heart rate (â‰¥20 beats per min) or blood pressure (â‰¥15 to 20 mm Hg) .
                                            <span class="Italics">[see Contraindications ( ) and Warnings and Precautions ( )]
                                                <a href="#s17">4</a><a href="#s21">5</a></span></p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Common Treatment-Emergent Adverse Reactions Associated with the Use of STRATTERA in Acute (up to 25 weeks) Adult Trials</span></caption>
<col align="left" width="62.054%">
<col align="left" width="18.973%">
<col align="left" width="18.973%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">Reactions reported by at least 2% of patients treated with atomoxetine, and greater than placebo. The following reactions did not meet this criterion but were reported by more atomoxetine-treated patients than placebo-treated patients and are possibly related to atomoxetine treatment: <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">peripheral coldness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>, <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">testicular pain</span>, <span class="product-label-link" type="condition" conceptid="4090570" conceptname="Painful orgasm">orgasm abnormal</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">micturition urgency</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstruation irregular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. The following reactions were reported by at least 2% of patients treated with atomoxetine, and equal to or less than placebo: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
                                                            <span class="Sup">a</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> includes the terms: <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>.
                                                            <span class="Sup">b</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the terms: sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
                                                            <span class="Sup">c</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> includes the terms: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4243368" conceptname="Initial insomnia">initial insomnia</span>, <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span>, and terminal <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.
                                                            <span class="Sup">d</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary hesitation</span> includes the terms: <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span>, <span class="product-label-link" type="condition" conceptid="195926" conceptname="Slowing of urinary stream">urine flow decreased</span>.
                                                            <span class="Sup">e</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote">Based on total number of males (STRATTERA, N=943; placebo, N=869).
                                                            <span class="Sup">f</span></p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">Based on total number of females (STRATTERA, N=754; placebo, N=691).
                                                            <span class="Sup">g</span></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Adverse Reaction</span><span class="Bold"><span class="Sup">a</span></span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">System Organ Class/Adverse Reaction
                                                            <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">STRATTERA (N=1697)
                                                            <br></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo (N=1560)
                                                            <br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">20</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
                                                        <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Feeling jittery</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutritional Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
                                                        <span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paraesthesia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
                                                        <span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Renal and Urinary Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary hesitation</span>
                                                        <span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span>
                                                        <span class="Sup">f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span>
                                                        <span class="Sup">g</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4036117" conceptname="Late ejaculation">Ejaculation delayed</span> and/or <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>
                                                        <span class="Sup">f</span><span class="Sup">f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p>The following adverse events occurred in at least 2% of adult CYP2D6 poor metaboliser (PM) patients and were statistically significantly more frequent in PM patients compared to CYP2D6 extensive metaboliser (EM) patients: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span> (4% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (35% of PMs, 17% of EMs); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (11% of PMs, 7% of EMs); <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span> (5% of PMs, 2% of EMs); <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (23% of PMs, 15% of EMs); <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (5% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (19% of PMs, 11% of EMs); <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span> (7% of PMs, 3% of EMs); <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span> (5% of PMs, 3% of EMs); terminal <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (3% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (6% of PMs, 1% of EMs); <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (21% of PMs, 9% of EMs); <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span> (6% of PMs, 2% of EMs); <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span> (15% of PMs, 7% of EMs); <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">peripheral coldness</span> (3% of PMs, 1% of EMs).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-6.1.9"></a><p></p>
<p class="First">â€” Atomoxetine appears to impair sexual function in some patients. Changes in sexual desire, sexual performance, and sexual satisfaction are not well assessed in most clinical trials because they need special attention and because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate the actual incidence. above displays the incidence of sexual side effects reported by at least 2% of adult patients taking STRATTERA in placebo-controlled trials.
                                            <span class="Underline">Male and female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span></span><a href="#t4">Table 4</a></p>
<p>There are no adequate and well-controlled studies examining <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> with STRATTERA treatment. While it is difficult to know the precise risk of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> associated with the use of STRATTERA, physicians should routinely inquire about such possible side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Spontaneous Reports</h2>
<p class="First">The following adverse reactions have been identified during post approval use of STRATTERA. Unless otherwise specified, these adverse reactions have occurred in adults and children and adolescents. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>â€” QT prolongation, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.
                                    <span class="Underline">Cardiovascular system</span></p>
<p>â€” Raynaud's phenomenon.
                                    <span class="Underline">Peripheral vascular effects</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span>.
                                    <span class="Underline">General disorders and administration site conditions</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoaesthesia</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span> in children and adolescents; <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span>; <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>.
                                    <span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>; <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, libido changes.
                                    <span class="Underline">Psychiatric disorders</span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in the postmarketing period. The postmarketing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> cases include patients with pre-existing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders and those with identified risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, as well as patients with neither a history of nor identified risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The exact relationship between STRATTERA and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is difficult to evaluate due to uncertainty about the background risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> patients.
                                    <span class="Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>â€” <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span>.
                                    <span class="Underline">Skin and subcutaneous tissue disorders</span></p>
<p>â€” Male <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>; <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span> in children and adolescents; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> in children and adolescents.
                                    <span class="Underline">Urogenital system</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s53"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Monoamine Oxidase Inhibitors</h2>
<p class="First">With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>) when taken in combination with an MAOI. Some cases presented with features resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Such reactions may occur when these drugs are given concurrently or in close proximity .
                                    <span class="Italics">[see Contraindications ( )]
                                        <a href="#s19">4.2</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effect of CYP2D6 Inhibitors on Atomoxetine</h2>
<p class="First">In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6-Â toÂ 8-fold and C , is about 3-Â toÂ 4-fold greater than atomoxetine alone.
                                    <span class="Sub">ss</span><span class="Sub">max</span></p>
<p>InÂ vitro studies suggest that coadministration of cytochromeÂ P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Antihypertensive Drugs and Pressor Agents</h2>
<p class="First">Because of possible effects on blood pressure, STRATTERA should be used cautiously with antihypertensive drugs and pressor agents (e.g., dopamine, dobutamine) or other drugs that increase blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Albuterol</h2>
<p class="First">STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta Â agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure. Albuterol (600Â mcgÂ iv over 2Â hours) induced increases in heart rate and blood pressure. These effects were potentiated by atomoxetine (60Â mg BID for 5Â days) and were most marked after the initial coadministration of albuterol and atomoxetine. However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol (200-800 mcg) and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were excluded for poor metabolizer status.
                                    <span class="Sub">2</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Effect of Atomoxetine on P450 Enzymes</h2>
<p class="First">Atomoxetine did not cause clinically important inhibition or induction of cytochromeÂ P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-7.5.1"></a><p></p>
<p class="First">â€” Coadministration of STRATTERA (60Â mg BID for 12Â days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5Â mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A.
                                            <span class="Underline">CYP3A Substrate (e.g., Midazolam)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-7.5.2"></a><p></p>
<p class="First">â€” Coadministration of STRATTERA (40Â or 60Â mg BID for 13Â days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50Â mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6.
                                            <span class="Underline">CYP2D6 Substrate (e.g., Desipramine)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Alcohol</h2>
<p class="First">Consumption of ethanol with STRATTERA did not change the intoxicating effects of ethanol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Methylphenidate</h2>
<p class="First">Coadministration of methylphenidate with STRATTERA did not increase cardiovascular effects beyond those seen with methylphenidate alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Drugs Highly Bound to Plasma Protein</h2>
<p class="First">InÂ vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations. Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Drugs that Affect GastricÂ pH</h2>
<p class="First">Drugs that elevate gastricÂ pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on STRATTERA bioavailability.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s65"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s66"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-8.1.1"></a><p></p>
<p class="First">â€” Pregnant rabbits were treated with up to 100Â mg/kg/day of atomoxetine by gavage throughout the period of organogenesis. At this dose, in 1 of 3 studies, a decrease in live fetuses and an increase in early resorptions was observed. Slight increases in the incidences of atypical origin of carotid artery and absent subclavian artery were observed. These findings were observed at doses that caused slight maternal toxicity. The no-effect dose for these findings was 30 mg/kg/day. The 100Â mg/kg dose is approximately 23 times the maximum human dose on a mg/m basis; plasma levels (AUC) of atomoxetine at this dose in rabbits are estimated to be 3.3 times (extensive metabolizers) or 0.4 times (poor metabolizers) those in humans receiving the maximum human dose.
                                            <span class="Underline">Pregnancy Category C</span><span class="Sup">2</span></p>
<p>Rats were treated with up to approximately 50Â mg/kg/day of atomoxetine (approximately 6 times the maximum human dose on a mg/m basis) in the diet from 2 weeks (females) or 10 weeks (males) prior to mating through the periods of organogenesis and lactation. In 1 of 2 studies, decreases in pup weight and pup survival were observed. The decreased pup survival was also seen at 25Â mg/kg (but not at 13Â mg/kg). In a study in which rats were treated with atomoxetine in the diet from 2 weeks (females) or 10 weeks (males) prior to mating throughout the period of organogenesis, a decrease in fetal weight (female only) and an increase in the incidence of incomplete ossification of the vertebral arch in fetuses were observed at 40Â mg/kg/day (approximately 5 times the maximum human dose on a mg/m basis) but not at 20Â mg/kg/day.
                                            <span class="Sup">2</span><span class="Sup">2</span></p>
<p>No adverse fetal effects were seen when pregnant rats were treated with up to 150Â mg/kg/day (approximately 17 times the maximum human dose on a mg/m basis) by gavage throughout the period of organogenesis.
                                            <span class="Sup">2</span></p>
<p>No adequate and well-controlled studies have been conducted in pregnant women. STRATTERA should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s68"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Parturition in rats was not affected by atomoxetine. The effect of STRATTERA on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s69"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Atomoxetine and/or its metabolites were excreted in the milk of rats. It is not known if atomoxetine is excreted in human milk. Caution should be exercised if STRATTERA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s70"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Anyone considering the use of STRATTERA in a child or adolescent must balance the potential risks with the clinical need .
                                    <span class="Italics">[see and Warnings and Precautions ( )]
                                        <a href="#s1">Boxed Warning</a><a href="#s22">5.1</a></span></p>
<p>The pharmacokinetics of atomoxetine in children and adolescents are similar to those in adults. The safety, efficacy, and pharmacokinetics of STRATTERA in pediatric patients less than 6 years of age have not been evaluated.</p>
<p>A study was conducted in young rats to evaluate the effects of atomoxetine on growth and neurobehavioral and sexual development. Rats were treated with 1, 10, or 50Â mg/kg/day (approximately 0.2, 2, and 8 times, respectively, the maximum human dose on a mg/m basis) of atomoxetine given by gavage from the early postnatal period (Day 10 of age) through adulthood. Slight delays in onset of vaginal patency (all doses) and preputial separation (10 and 50Â mg/kg), slight decreases in epididymal weight and sperm number (10 and 50Â mg/kg), and a slight decrease in corpora lutea (50Â mg/kg) were seen, but there were no effects on fertility or reproductive performance. A slight delay in onset of incisor <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span> was seen at 50Â mg/kg. A slight increase in motor activity was seen on Day 15 (males at 10 and 50Â mg/kg and females at 50Â mg/kg) and on Day 30 (females at 50Â mg/kg) but not on Day 60 of age. There were no effects on learning and memory tests. The significance of these findings to humans is unknown.
                                    <span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s71"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The safety, efficacy and pharmacokinetics of STRATTERA in geriatric patients have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Atomoxetine exposureÂ (AUC) is increased, compared with normal subjects, in EM subjects with moderate (Child-Pugh ClassÂ B) (2-fold increase) and severe (Child-Pugh ClassÂ C) (4-fold increase) <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Dosage adjustment is recommended for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> .
                                    <span class="Italics">[seeÂ Dosage and Administration ( )]
                                        <a href="#s12">2.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">EM subjects with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> had higher systemic exposure to atomoxetine than healthy subjects (about a 65%Â increase), but there was no difference when exposure was corrected for mg/kgÂ dose. STRATTERA can therefore be administered to <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or lesser degrees of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> using the normal dosing regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Gender</h2>
<p class="First">Gender did not influence atomoxetine disposition.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-8.9"></a><p></p>
<h2>8.9 Ethnic Origin</h2>
<p class="First">Ethnic origin did not influence atomoxetine disposition (except that PMs are more common in Caucasians).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-8.10"></a><p></p>
<h2>8.10 Patients with Concomitant Illness</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-8.10.1"></a><p></p>
<p class="First">â€” Atomoxetine administered in a flexible dose range of 0.5 to 1.5Â mg/kg/day (mean dose of 1.3 mg/kg/day) and placebo were compared in 148 randomized pediatric (age 7-17 years) subjects with a DSM-IV diagnosis of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and comorbid tic disorder in an 18 week, double-blind, placebo-controlled study in which the majority (80%) enrolled in this trial with Tourette's Disorder (Tourette's Disorder: 116 subjects; chronic <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">motor tic</span> disorder: 29 subjects). A non-inferiority analysis revealed that STRATTERA did not worsen <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> in these patients as determined by the Yale Global Tic Severity Scale Total Score (YGTSS). Out of 148 patients who entered the acute treatment phase, 103 (69.6%) patients discontinued the study. The primary reason for discontinuation in both the atomoxetine (38 of 76 patients, 50.0%) and placebo (45 of 72 patients, 62.5%) treatment groups was identified as lack of efficacy with most of the patients discontinuing at Week 12. This was the first visit where patients with a CGI-Sâ‰¥4 could also meet the criteria for â€œclinical non-responderâ€? (CGI-S remained the same or increased from study baseline) and be eligible to enter an open-label extension study with atomoxetine. There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> .
                                            <span class="Underline"><span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">Tics</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and comorbid Tourette's Disorder</span><span class="Italics">[see Adverse Reactions ( )]
                                                <a href="#s52">6.2</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-8.10.2"></a><p></p>
<p class="First">â€“ In two post-marketing, double-blind, placebo-controlled trials, it has been demonstrated that treating patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and comorbid <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> with STRATTERA does not worsen their <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.
                                            <span class="Underline"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and comorbid <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">Anxiety Disorders</span></span></p>
<p>In a 12-week double-blind, placebo-controlled trial, 176 patients, aged 8-17, who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and at least one of the <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> of separation <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorder</span>, <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">generalized anxiety disorder</span> or social <span class="product-label-link" type="condition" conceptid="440985" conceptname="Phobia">phobia</span> were randomized. Following a 2-week double-blind placebo lead-in, STRATTERA was initiated at 0.8 mg/kg/day with increase to a target dose of 1.2 mg/kg/day (median dose 1.30 mg/kg/day +/- 0.29 mg/kg/day). STRATTERA did not worsen <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> in these patients as determined by the Pediatric <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> Rating Scale (PARS). Of the 158 patients who completed the double-blind placebo lead-in, 26 (16%) patients discontinued the study.</p>
<p>In a separate 16-week, double-blind, placebo-controlled trial, 442Â patients aged 18-65, who met DSM-IV criteria for adult <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and <span class="product-label-link" type="condition" conceptid="440690" conceptname="Social phobia">social anxiety disorder</span> (23% of whom also had <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span>) were randomized. Following a 2-week double-blind placebo lead-in, STRATTERA was initiated at 40Â mg/day to a maximum dose of 100Â mg/day (mean daily dose 83Â mg/day +/- 19.5Â mg/day). STRATTERA did not worsen <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> in these patients as determined by the Liebowitz Social <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> Scale (LSAS). Of the 413Â patients who completed the double-blind placebo lead-in, 149 (36.1%) patients discontinued the study. There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> .
                                            <span class="Italics">[see Adverse Reactions ( )]
                                                <a href="#s52">6.2</a></span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s79"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="s80"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">STRATTERA is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="s81"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">In a randomized, double-blind, placebo-controlled, abuse-potential study in adults comparing effects of STRATTERA and placebo, STRATTERA was not associated with a pattern of response that suggested stimulant or euphoriant properties.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="s82"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Clinical study data in over 2000Â children, adolescents, and adults with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> and over 1200Â adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> showed only isolated incidents of drug diversion or inappropriate self-administration associated with STRATTERA. There was no evidence of symptom rebound or adverse reactions suggesting a drug-discontinuation or withdrawal syndrome.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-9.3.1"></a><p></p>
<p class="First">â€” Drug discrimination studies in rats and monkeys showed inconsistent stimulus generalization between atomoxetine and cocaine.
                                            <span class="Underline">Animal Experience</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s84"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">No fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> occurred in clinical trials. There is limited clinical trial experience with STRATTERA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. During postmarketing, there have been fatalities reported involving a mixed ingestion <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of STRATTERA and at least one other drug. There have been no reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> involving <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of STRATTERA alone, including <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdoses</span> at amounts up to 1400 mg. In some cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving STRATTERA, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported. The most commonly reported symptoms accompanying acute and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">chronic overdoses</span> of STRATTERA were <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and abnormal behavior. <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> have also been reported. Signs and symptoms consistent with mild to moderate sympathetic nervous system activation (e.g.,Â <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>) have also been observed. Most events were mild to moderate. Less commonly, there have been reports of QT prolongation and mental changes, including <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> .
                                    <span class="Italics">[see Clinical Pharmacology ( )]
                                        <a href="#s90">12.2</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">Consult with a Certified Poison Control Center for up to date guidance and advice. Because atomoxetine is highly protein-bound, dialysis is not likely to be useful in the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s87"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">STRATTERA (atomoxetine) is a selective norepinephrine reuptake inhibitor. AtomoxetineÂ HCl is the (-) isomer as determined by x-ray diffraction. The chemical designation is (-)- -Methyl-3-phenyl-3-( -tolyloxy)-propylamine hydrochloride. The molecular formula is C H NOâ€¢HCl, which corresponds to a molecular weightÂ ofÂ 291.82. The chemical structure is:
                            <span class="Sup">Â®</span><span class="Italics">R</span><span class="Italics">N</span><span class="Italics">o</span><span class="Sub">17</span><span class="Sub">21</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6a7584b5-524d-4726-86a2-1b08e422f60e&amp;name=strattera1.jpg">
</div>
<p>AtomoxetineÂ HCl is a white to practically white solid, which has a solubility of 27.8Â mg/mL in water.</p>
<p>STRATTERA capsules are intended for oral administration only.</p>
<p>Each capsule contains atomoxetineÂ HCl equivalent toÂ 10, 18, 25, 40, 60, 80, or 100Â mg of atomoxetine. The capsules also contain pregelatinized starch and dimethicone. The capsule shells contain gelatin, sodium lauryl sulfate, and other inactive ingredients. The capsule shells also contain one or more of the following:</p>
<p>FD&amp;C Blue No.Â 2, synthetic yellow iron oxide, titanium dioxide, red iron oxide. The capsules are imprinted with edible black ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s88"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s89"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> DisorderÂ (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in exÂ vivo uptake and neurotransmitter depletion studies.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s90"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">An exposure-response analysis encompassing doses of atomoxetine (0.5, 1.2 or 1.8 mg/kg/day) or placebo demonstrated atomoxetine exposure correlates with efficacy as measured by the Attention-Deficit/<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder Rating Scale-IV-Parent Version: Investigator administered and scored. The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline .
                                    <span class="Italics">[see Clinical Studies ( )]
                                        <a href="#s103">14.2</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="e90"></a><a name="section-12.2.1"></a><p></p>
<p class="First">â€” The effect of STRATTERA on QTc prolongation was evaluated in a randomized, double-blinded, positive-(moxifloxacin 400Â mg) and placebo-controlled, cross-over study in healthy male CYP2D6 poor metabolizers. A total of 120 healthy subjects were administered STRATTERA (20Â mg and 60Â mg) twice daily for 7 days. No large changes in QTc interval (i.e., increases &gt;60Â msec from baseline, absolute QTc &gt;480Â msec) were observed in the study. However, small changes in QTc interval cannot be excluded from the current study, because the study failed to demonstrate assay sensitivity. There was a slight increase in QTc interval with increased atomoxetine concentration.
                                            <span class="Underline">Cardiac Electrophysiology</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s91"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450Â 2D6Â (CYP2D6) enzymatic pathway and subsequent glucuronidation. Atomoxetine has a half-life of about 5Â hours. A fraction of the population (about 7%Â of Caucasians and 2%Â of African Americans) are poor metabolizersÂ (PMs) of CYP2D6 metabolized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24Â hours) of atomoxetine compared with people with normal activity [extensive metabolizersÂ (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.</p>
<p>The pharmacokinetics of atomoxetine have been evaluated in more than 400Â children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies. Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults. When doses were normalized to a mg/kgÂ basis, similar half-life, C , and AUCÂ values were observed in children, adolescents, and adults. Clearance and volume of distribution after adjustment for body weight were also similar.
                                    <span class="Sub">max</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s92"></a><a name="section-12.3.1"></a><p></p>
<p class="First">â€” Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of aboutÂ 63% in EMs and 94%Â in PMs. Maximal plasma concentrationsÂ (C ) are reached approximately 1Â to 2Â hours after dosing.
                                            <span class="Underline">Absorption and distribution</span><span class="Sub">max</span></p>
<p>STRATTERA can be administered with or without food. Administration of STRATTERA with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetineÂ (AUC), but did decrease the rate of absorption, resulting in a 37%Â lower C , and delayed T by 3Â hours. In clinical trials with children and adolescents, administration of STRATTERA with food resulted in a 9%Â lowerÂ C .
                                            <span class="Sub">max</span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>The steady-state volume of distribution after intravenous administration is 0.85Â L/kg indicating that atomoxetine distributes primarily into total body water. Volume of distribution is similar across the patient weight range after normalizing for body weight.</p>
<p>At therapeutic concentrations, 98%Â of atomoxetine in plasma is bound to protein, primarily albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s93"></a><a name="section-12.3.2"></a><p></p>
<p class="First">â€” Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathwayÂ (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activityÂ (EMs). For PMs, AUC of atomoxetine is approximately 10-fold and C is about 5-fold greater than EMs. Laboratory tests are available to identify CYP2D6Â PMs. Coadministration of STRATTERA with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary . Atomoxetine did not inhibit or induce the CYP2D6Â pathway.
                                            <span class="Underline">Metabolism and elimination</span><span class="Sub">ss, max</span><span class="Italics">[see Warnings and Precautions ( )]
                                                <a href="#s40">5.13</a></span></p>
<p>The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochromeÂ P450 enzymes. N-Desmethylatomoxetine is formed by CYP2C19 and other cytochromeÂ P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).</p>
<p>Mean apparent plasma clearance of atomoxetine after oral administration in adult EMs is 0.35Â L/hr/kg and the mean half-life is 5.2Â hours. Following oral administration of atomoxetine to PMs, mean apparent plasma clearance is 0.03Â L/hr/kg and mean half-life is 21.6Â hours. For PMs, AUC of atomoxetine is approximately 10-fold and C is about 5-fold greater than EMs. The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6Â toÂ 8Â hours) in EMÂ subjects, while the half-life of N-desmethylatomoxetine is much longer in PMÂ subjects (34Â toÂ 40Â hours).
                                            <span class="Sub">ss, max</span></p>
<p>Atomoxetine is excreted primarily as 4-hydroxyatomoxetine- -glucuronide, mainly in the urine (greater than 80%Â of the dose) and to a lesser extent in the feces (less than 17%Â of the dose). Only a small fraction of the STRATTERA dose is excreted as unchanged atomoxetine (less than 3%Â of the dose), indicating extensive biotransformation.
                                            <span class="Italics">O</span></p>
<p>.
                                            <span class="Italics">[See Use In Specific Populations ( , , , , , )]
                                                <a href="#s70">8.4</a><a href="#s71">8.5</a><a href="#s72">8.6</a><a href="#s73">8.7</a><a href="#s74">8.8</a><a href="#s75">8.9</a></span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s94"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s95"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-13.1.1"></a><p></p>
<p class="First">â€” AtomoxetineÂ HCl was not carcinogenic in rats and mice when given in the diet for 2Â years at time-weighted average doses up to 47Â and 458Â mg/kg/day, respectively. The highest dose used in rats is approximately 8Â andÂ 5Â times the maximum human dose in children and adults, respectively, on a mg/m Â basis. Plasma levels (AUC) of atomoxetine at this dose in rats are estimated to be 1.8Â times (extensive metabolizers) or 0.2Â times (poor metabolizers) those in humans receiving the maximum human dose. The highest dose used in mice is approximately 39Â andÂ 26Â times the maximum human dose in children and adults, respectively, on a mg/m Â basis.
                                            <span class="Underline">Carcinogenesis</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s97"></a><a name="section-13.1.2"></a><p></p>
<p class="First">â€” AtomoxetineÂ HCl was negative in a battery of genotoxicity studies that included a reverse point mutation assay (AmesÂ Test), an inÂ vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, a chromosomal aberration test in Chinese hamster ovary cells, an unscheduled DNA synthesis test in rat hepatocytes, and an inÂ vivo micronucleus test in mice. However, there was a slight increase in the percentage of Chinese hamster ovary cells with diplochromosomes, suggesting endoreduplication (numerical aberration).
                                            <span class="Underline">Mutagenesis</span></p>
<p>The metabolite N-desmethylatomoxetineÂ HCl was negative in the AmesÂ Test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and unscheduled DNA synthesis test.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s98"></a><a name="section-13.1.3"></a><p></p>
<p class="First">â€” AtomoxetineÂ HCl did not impair fertility in rats when given in the diet at doses of up to 57Â mg/kg/day, which is approximately 6Â times the maximum human dose on a mg/m Â basis.
                                            <span class="Underline">Impairment of fertility</span><span class="Sup">2</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s99"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s100"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> studies in Children and Adolescents</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s101"></a><a name="section-14.1.1"></a><p></p>
<p class="First">â€” The effectiveness of STRATTERA in the treatment of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> was established in 4Â randomized, double-blind, placebo-controlled studies of pediatric patients (agesÂ 6Â toÂ 18). Approximately one-third of the patients met DSM-IV criteria for inattentive subtype and two-thirds met criteria for both inattentive and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>/impulsive subtypes.
                                            <span class="Underline">Acute Studies</span></p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> were evaluated by a comparison of mean change from baseline to endpoint for STRATTERA- and placebo-treated patients using an intent-to-treat analysis of the primary outcome measure, the investigator administered and scored <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> Rating Scale-IV-Parent VersionÂ (ADHDRS) total score including <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>/impulsive and inattentive subscales. Each item on the ADHDRS maps directly to oneÂ symptom criterion for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> in the DSM-IV.</p>
<p>In StudyÂ 1, an 8-week randomized, double-blind, placebo-controlled, dose-response, acute treatment study of children and adolescents agedÂ 8Â toÂ 18Â (N=297), patients received either a fixed dose of STRATTERAÂ (0.5, 1.2, or 1.8Â mg/kg/day) or placebo. STRATTERA was administered as a divided dose in the early morning and late afternoon/early evening. At the 2Â higher doses, improvements in <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms were statistically significantly superior in STRATTERA-treated patients compared with placebo-treated patients as measured on the ADHDRS scale. The 1.8 mg/kg/day STRATTERA dose did not provide any additional benefit over that observed with the 1.2 mg/kg/day dose. The 0.5 mg/kg/day STRATTERA dose was not superior to placebo.</p>
<p>In StudyÂ 2, a 6-week randomized, double-blind, placebo-controlled, acute treatment study of children and adolescents agedÂ 6Â toÂ 16Â (N=171), patients received either STRATTERA or placebo. STRATTERA was administered as a single dose in the early morning and titrated on a weight-adjusted basis according to clinical response, up to a maximum dose of 1.5Â mg/kg/day. The mean final dose of STRATTERA was approximately 1.3Â mg/kg/day. <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms were statistically significantly improved on STRATTERA compared with placebo, as measured on the ADHDRS scale. This study shows that STRATTERA is effective when administered once daily in the morning.</p>
<p>In 2Â identical, 9-week, acute, randomized, double-blind, placebo-controlled studies of children agedÂ 7Â toÂ 13 (StudyÂ 3, N=147; StudyÂ 4, N=144), STRATTERA and methylphenidate were compared with placebo. STRATTERA was administered as a divided dose in the early morning and late afternoon (after school) and titrated on a weight-adjusted basis according to clinical response. The maximum recommended STRATTERA dose was 2.0Â mg/kg/day. The mean final dose of STRATTERA for both studies was approximately 1.6Â mg/kg/day. In both studies, <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms statistically significantly improved more on STRATTERA than on placebo, as measured on the ADHDRS scale.</p>
<p>Examination of population subsets based on gender and age (&lt;12Â and 12Â toÂ 17) did not reveal any differential responsiveness on the basis of these subgroupings. There was not sufficient exposure of ethnic groups other than Caucasian to allow exploration of differences in these subgroups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s102"></a><a name="section-14.1.2"></a><p></p>
<p class="First">â€” The effectiveness of STRATTERA in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> was established in an outpatient study of children and adolescents (ages 6-15 years). Patients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> who showed continuous response for about 4 weeks during an initial 10 week open-label treatment phase with STRATTERA (1.2 to 1.8 mg/kg/day) were randomized to continuation of their current dose of STRATTERA (N=292) or to placebo (N=124) under double-blind treatment for observation of relapse. Response during the open-label phase was defined as CGI-<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>-S score â‰¤2 and a reduction of at least 25% from baseline in ADHDRS-IV-Parent:Inv total score. Patients who were assigned to STRATTERA and showed continuous response for approximately 8 months during the first double-blind treatment phase were again randomized to continuation of their current dose of STRATTERA (N=81) or to placebo (N=82) under double-blind treatment for observation of relapse. Relapse during the double-blind phase was defined as CGI-<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>-S score increases of at least 2 from the end of open-label phase and ADHDRS-IV-Parent:Inv total score returns to â‰¥90% of study entry score for 2 consecutive visits. In both double-blind phases, patients receiving continued STRATTERA treatment experienced significantly longer times to relapse than those receiving placebo.
                                            <span class="Underline">Maintenance Study</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s103"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> studies in Adults</h2>
<p class="First">The effectiveness of STRATTERA in the treatment of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> was established in 2Â randomized, double-blind, placebo-controlled clinical studies of adult patients, ageÂ 18 and older, who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>.</p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> were evaluated using the investigator-administered Conners Adult <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> Rating Scale Screening VersionÂ (CAARS), a 30-item scale. The primary effectiveness measure was the 18-item Total <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> Symptom score (the sum of the inattentive and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>/impulsivity subscales from the CAARS) evaluated by a comparison of mean change from baseline to endpoint using an intent-to-treat analysis.</p>
<p>In 2Â identical, 10-week, randomized, double-blind, placebo-controlled acute treatment studies (StudyÂ 5, N=280; StudyÂ 6, N=256), patients received either STRATTERA or placebo. STRATTERA was administered as a divided dose in the early morning and late afternoon/early evening and titrated according to clinical response in a range of 60Â toÂ 120Â mg/day. The mean final dose of STRATTERA for both studies was approximately 95Â mg/day. In both studies, <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms were statistically significantly improved on STRATTERA, as measured on the <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> Symptom score from the CAARS scale.</p>
<p>Examination of population subsets based on gender and age (&lt;42Â andÂ â‰¥42) did not reveal any differential responsiveness on the basis of these subgroupings. There was not sufficient exposure of ethnic groups other than Caucasian to allow exploration of differences in these subgroups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s104"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:68151-4484-3 in a PACKAGE of 1 CAPSULES</p>
<div class="Section" data-sectionCode="34069-5">
<a name="s105"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<table width="100%">
<col align="left" width="14.852%">
<col align="left" width="12.164%">
<col align="left" width="12.164%">
<col align="left" width="12.164%">
<col align="left" width="12.164%">
<col align="left" width="12.164%">
<col align="left" width="12.164%">
<col align="left" width="12.164%">
<tfoot><tr class="First Last"><td align="left" colspan="8" valign="top"><p class="First Footnote">Atomoxetine base equivalent.
                                                    <span class="Sup">a</span></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">STRATTERA Capsules
                                                    <span class="Sup">Â®</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">10 mg
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">18 mg
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">25 mg
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">40 mg
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">60 mg
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">80 mg
                                                    <span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">100 mg
                                                    <span class="Sup">a</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Color</span></td>
<td class="Botrule Rrule" align="left" valign="top">Opaque White, Opaque White
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Gold, Opaque White
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Opaque Blue, Opaque White
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Opaque Blue, Opaque Blue
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Opaque Blue, Gold
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Opaque Brown, Opaque White
                                                <br>
</td>
<td class="Botrule Rrule" align="left" valign="top">Opaque Brown, Opaque Brown
                                                <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Identification</span></td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3227</td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3238</td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3228</td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3229</td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3239</td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3250</td>
<td class="Botrule Rrule" align="left" valign="top">LILLY 3251</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">10 mg</td>
<td class="Botrule Rrule" align="left" valign="top">18 mg</td>
<td class="Botrule Rrule" align="left" valign="top">25 mg</td>
<td class="Botrule Rrule" align="left" valign="top">40 mg</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg</td>
<td class="Botrule Rrule" align="left" valign="top">80 mg</td>
<td class="Botrule Rrule" align="left" valign="top">100 mg</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top"><span class="Bold">NDC Codes:</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Bottles of 30</span></td>
<td class="Botrule Rrule" align="left" valign="top">0002-3227-30</td>
<td class="Botrule Rrule" align="left" valign="top">0002-3238-30</td>
<td class="Botrule Rrule" align="left" valign="top">0002-3228-30</td>
<td class="Botrule Rrule" align="left" valign="top">0002-3229-30</td>
<td class="Botrule Rrule" align="left" valign="top">0002-3239-30</td>
<td class="Botrule Rrule" align="left" valign="top">0002-3250-30</td>
<td class="Botrule Rrule" align="left" valign="top">0002-3251-30</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s106"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 25Â°CÂ (77Â°F); excursions permitted to 15Â°Â toÂ 30Â°C (59Â°Â toÂ 86Â°F) [seeÂ USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s107"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved Medication Guide.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s108"></a><a name="section-16.1"></a><p></p>
<h2>17.1 General Information</h2>
<p class="First">Physicians should instruct their patients to read the Medication Guide before starting therapy with STRATTERA and to reread it each time the prescription is renewed.</p>
<p>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with STRATTERA and should counsel them in its appropriate use. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.</p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking STRATTERA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s109"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during STRATTERA treatment and when the dose is adjusted. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s110"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></h2>
<p class="First">Patients initiating STRATTERA should be cautioned that severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> may develop. Patients should be instructed to contact their physician immediately should they develop <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, dark urine, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or unexplained â€œflu-likeâ€? symptoms .
                                    <span class="Italics">[see Warnings and Precautions ( )]
                                        <a href="#s23">5.2</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s111"></a><a name="section-16.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span></h2>
<p class="First">Patients should be instructed to call their doctor as soon as possible should they notice an increase in <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s112"></a><a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></h2>
<p class="First">Rare postmarketing cases of <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, defined as painful and nonpainful penile erection lasting more than 4 hours, have been reported for pediatric and adult patients treated with STRATTERA. The parents or guardians of pediatric patients taking STRATTERA and adult patients taking STRATTERA should be instructed that <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> requires prompt medical attention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s113"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Ocular Irritant</h2>
<p class="First">STRATTERA is an ocular irritant. STRATTERA capsules are not intended to be opened. In the event of capsule content coming in contact with the eye, the affected eye should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> immediately with water, and medical advice obtained. Hands and any potentially contaminated surfaces should be washed as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s114"></a><a name="section-16.7"></a><p></p>
<h2>17.7 Drug-Drug Interaction</h2>
<p class="First">Patients should be instructed to consult a physician if they are taking or plan to take any prescription or over-the-counter medicines, dietary supplements, or herbal remedies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s115"></a><a name="section-16.8"></a><p></p>
<h2>17.8 Pregnancy</h2>
<p class="First">Patients should be instructed to consult a physician if they are nursing, pregnant, or thinking of becoming pregnant while taking STRATTERA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s116"></a><a name="section-16.9"></a><p></p>
<h2>17.9 Food</h2>
<p class="First">Patients may take STRATTERA with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s117"></a><a name="section-16.10"></a><p></p>
<h2>17.10 Missed Dose</h2>
<p class="First">If patients miss a dose, they should be instructed to take it as soon as possible, but should not take more than the prescribed total daily amount of STRATTERA in any 24-hour period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s118"></a><a name="section-16.11"></a><p></p>
<h2>17.11 Interference with Psychomotor Performance</h2>
<p class="First">Patients should be instructed to use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s119"></a><a name="section-17"></a><p></p>
<p class="First">Literature revised February 20, 2014</p>
<p><span class="Bold">Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA www.strattera.com
                                <br><br></span></p>
<p>Copyright Â© 2002, 2014, Eli Lilly and Company. All rights reserved.</p>
<p>PV 9436 AMP</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s120"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE STRATTERA
                                <br><span class="Sup">Â®</span></span><span class="Bold">(Stra-TAIR-a)</span><br><span class="Bold">(atomoxetine) Capsules</span></p>
<p>Read the Medication Guide that comes with STRATTERA before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your treatment or your child's treatment with STRATTERA.
                            <span class="Sup">Â®</span></p>
<p><a name="p1"></a><span class="Bold Underline">What is the most important information I should know about STRATTERA?</span></p>
<p><span class="Bold">The following have been reported with use of STRATTERA:</span></p>
<p><span class="Bold Underline">1. Suicidal thoughts and actions in children and teenagers:</span></p>
<p>Although no <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in these studies, 4 out of every 1000 patients developed suicidal thoughts. Tell your child or teenager's doctor if your child or teenager (or there is a family history of):
                            <span class="Bold">Children and teenagers sometimes think about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, and many report trying to kill themselves. Results from STRATTERA clinical studies with over 2200 child or teenage <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> patients suggest that some children and teenagers may have a higher chance of having suicidal thoughts or actions.</span></p>
<ul class="Disc">
<li>has bipolar illness (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>)</li>
<li>had <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> thoughts or actions before starting STRATTERA</li>
</ul>
<p><span class="Bold">The chance for suicidal thoughts and actions may be higher:</span></p>
<ul class="Disc">
<li>early during STRATTERA treatment</li>
<li>during dose adjustments</li>
</ul>
<p><span class="Bold">Prevent suicidal thoughts and action in your child or teenager by:</span></p>
<ul class="Disc">
<li>paying close attention to your child or teenager's moods, behaviors, thoughts, and feelings during STRATTERA treatment</li>
<li>keeping all follow-up visits with your child or teenager's doctor as scheduled</li>
</ul>
<p><span class="Bold">Watch for the following signs in your child or teenager during STRATTERA treatment:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li><span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span></li>
<li>impulsivity</li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> thoughts</li>
</ul>
<p>Your child or teenager may need to be closely watched for suicidal thoughts and actions or need a change in medicine.
                            <span class="Bold">Call your child or teenager's doctor right away if they have any of the above signs, especially if they are new, sudden, or severe.</span></p>
<p><span class="Bold Underline">2. Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>:</span></p>
<p><span class="Bold">STRATTERA can cause <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> in some patients. Call your doctor right away if you or your child has the following signs of liver problems:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>right upper belly <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>dark urine</li>
<li><span class="product-label-link" type="condition" conceptid="4021666" conceptname="Yellow skin">yellow skin</span> or eyes</li>
<li>unexplained flu-like symptoms</li>
</ul>
<p><span class="Bold Underline">3. Heart-related problems:</span></p>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients who have heart problems or heart defects</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in adults</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and heart rate</span></li>
</ul>
<p>Tell your doctor if you or your child has any heart problems, heart defects, high blood pressure, or a family history of these problems. Your doctor should check you or your child carefully for heart problems before starting STRATTERA.</p>
<p>Your doctor should check your blood pressure or your child's blood pressure and heart rate regularly during treatment with STRATTERA.</p>
<p><span class="Bold">Call your doctor right away if you or your child has any signs of heart problems such as <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> while taking STRATTERA.</span></p>
<p><span class="Bold Underline">4. New mental (psychiatric) problems in children and teenagers:</span></p>
<ul class="Disc"><li>new <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms (such as hearing voices, believing things that are not true, being suspicious) or new <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms</li></ul>
<p>because adjusting or stopping STRATTERA treatment may need to be considered.
                            <span class="Bold">Call your child or teenager's doctor right away about any new mental symptoms</span></p>
<p><span class="Bold">What Is STRATTERA?</span></p>
<p>STRATTERA is a selective norepinephrine reuptake inhibitor medicine. It is used for the treatment of attention deficit and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>). STRATTERA may help increase attention and decrease impulsiveness and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>.</p>
<p>STRATTERA should be used as a part of a total treatment program for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> that may include counseling or other therapies.</p>
<p>STRATTERA has not been studied in children less than 6 years old.</p>
<p><span class="Bold">Who should not take STRATTERA?</span></p>
<p><span class="Bold">STRATTERA should not be taken if you or your child:</span></p>
<ul class="Disc">
<li>are taking or have taken within the past 14 days an anti-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> medicine called a monoamine oxidase inhibitor or MAOI. Some names of MAOI medicines are Nardil (phenelzine sulfate), Parnate (tranylcypromine sulfate) and Emsam (selegiline transdermal system).
                                <span class="Sup">Â®</span><span class="Sup">Â®</span><span class="Sup">Â®</span>
</li>
<li>have an eye problem called narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></li>
<li>are allergic to anything in STRATTERA. See the end of this Medication Guide for a complete list of ingredients.</li>
<li>have or have had a rare tumor called <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</li>
</ul>
<p><span class="Bold">STRATTERA may not be right for you or your child. Before starting STRATTERA tell your doctor or your child's doctor about all health conditions (or a family history of) including:</span></p>
<ul class="Disc">
<li>have or had <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> thoughts or actions</li>
<li>heart problems, heart defects, irregular heart beat, high blood pressure, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li>mental problems, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, bipolar illness, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>liver problems</li>
</ul>
<p>Tell your doctor if you or your child is pregnant, planning to become pregnant, or breastfeeding.</p>
<p><span class="Bold">Can STRATTERA be taken with other medicines?</span></p>
<p>STRATTERA and some medicines may interact with each other and cause serious side effects. Your doctor will decide whether STRATTERA can be taken with other medicines.
                            <span class="Bold">Tell your doctor about all the medicines that you or your child takes including prescription and nonprescription medicines, vitamins, and herbal supplements.</span></p>
<p><span class="Bold">Especially tell your doctor if you or your child takes:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medicines</li>
<li>anti-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> medicines including MAOIs</li>
<li>blood pressure medicines</li>
<li><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> medicines that contain decongestants</li>
</ul>
<p>Know the medicines that you or your child takes. Keep a list of your medicines with you to show your doctor and pharmacist.</p>
<p><span class="Bold">Do not start any new medicine while taking STRATTERA without talking to your doctor first.</span></p>
<p><span class="Bold">How should STRATTERA be taken?</span></p>
<ul class="Disc">
<li>Your doctor may adjust the dose until it is right for you or your child.
                                <span class="Bold">Take STRATTERA exactly as prescribed. STRATTERA comes in different dose strength capsules.</span>
</li>
<li>Swallow STRATTERA capsules whole with water or other liquids. Tell your doctor if you or your child cannot swallow STRATTERA whole. A different medicine may need to be prescribed.
                                <span class="Bold">Do not chew, crush, or open the capsules.</span>
</li>
<li>Avoid touching a broken STRATTERA capsule. Wash hands and surfaces that touched an open STRATTERA capsule. If any of the powder gets in your eyes or your child's eyes, rinse them with water right away and call your doctor.</li>
<li>STRATTERA can be taken with or without food.</li>
<li>STRATTERA is usually taken once or twice a day. Take STRATTERA at the same time each day to help you remember. If you miss a dose of STRATTERA, take it as soon as you remember that day. If you miss a day of STRATTERA, do not double your dose the next day. Just skip the day you missed.</li>
<li>From time to time, your doctor may stop STRATTERA treatment for a while to check <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms.</li>
<li>Your doctor may do regular checks of the blood, heart, and blood pressure while taking STRATTERA. Children should have their height and weight checked often while taking STRATTERA. STRATTERA treatment may be stopped if a problem is found during these check-ups.</li>
<li><span class="Bold">If you or your child takes too much STRATTERA or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, call your doctor or poison control center right away, or get emergency treatment.</span></li>
</ul>
<p><span class="Bold">What are possible side effects of STRATTERA?</span></p>
<p>See for information on reported suicidal thoughts and actions, other mental problems, severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, and heart problems.
                            <span class="Bold">â€œ â€?
                                <a href="#p1">What is the most important information I should know about STRATTERA?</a></span></p>
<p><span class="Bold">Other serious side effects include:</span></p>
<ul class="Disc">
<li>serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (call your doctor if you have trouble breathing, see <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or experience other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>)</li>
<li>slowing of growth (height and weight) in children</li>
<li>problems passing urine including
                                <ul class="Disc">
<li>trouble starting or keeping a urine stream</li>
<li>cannot fully empty the bladder</li>
</ul>
</li>
</ul>
<p><span class="Bold">Common side effects in children and teenagers include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span></li>
</ul>
<p><span class="Bold">Common side effects in adults include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>sexual side effects</li>
<li>problems passing urine</li>
</ul>
<p><span class="Bold">Other information for children, teenagers, and adults:</span></p>
<ul class="Disc">
<li>Erections that won't go away (<span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>) have occurred rarely during treatment with STRATTERA. If you have an erection that lasts more than 4 hours, seek medical help right away. Because of the potential for lasting damage, including the potential inability to have erections, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> should be evaluated by a doctor immediately.</li>
<li>STRATTERA may affect your ability or your child's ability to drive or operate heavy machinery. Be careful until you know how STRATTERA affects you or your child.</li>
<li>Talk to your doctor if you or your child has side effects that are bothersome or do not go away.</li>
</ul>
<p>This is not a complete list of possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store STRATTERA?</span></p>
<ul class="Disc">
<li>Store STRATTERA in a safe place at room temperature, 59 to 86Â°F (15 to 30Â°C).</li>
<li><span class="Bold">Keep STRATTERA and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General information about STRATTERA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use STRATTERA for a condition for which it was not prescribed. Do not give STRATTERA to other people, even if they have the same condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about STRATTERA. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about STRATTERA that was written for healthcare professionals. For more information about STRATTERA call 1-800-Lilly-Rx (1-800-545-5979) or visit www.strattera.com.</p>
<p><span class="Bold">What are the ingredients in STRATTERA?</span></p>
<p>atomoxetine hydrochloride.
                            <span class="Bold">Active ingredient:</span></p>
<p>pregelatinized starch, dimethicone, gelatin, sodium lauryl sulfate, FD&amp;C Blue No.Â 2, synthetic yellow iron oxide, titanium dioxide, red iron oxide, and edible black ink.
                            <span class="Bold">Inactive ingredients:</span></p>
<p>Nardil is a registered trademark of Pfizer Inc.
                            <span class="Sup">Â®</span></p>
<p>Parnate is a registered trademark of GlaxoSmithKline.
                            <span class="Sup">Â®</span></p>
<p>Emsam is a registered trademark of Somerset Pharmaceuticals Inc.
                            <span class="Sup">Â®</span></p>
<p><span class="Italics">This Medication Guide has been approved by the US Food and Drug Administration.</span></p>
<p>Patient Information revised February 20, 2014</p>
<p><span class="Bold">Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA
                                <br></span></p>
<p><span class="Bold">www.strattera.com</span></p>
<p>Copyright Â© 2003, 2014, Eli Lilly and Company. All rights reserved.</p>
<p>PV 5859 AMP</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s121"></a><a name="section-19"></a><p></p>
<h1>Atomoxetine HCl</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6a7584b5-524d-4726-86a2-1b08e422f60e&amp;name=68151-4484.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>STRATTERAÂ 		
					</strong><br><span class="contentTableReg">atomoxetine hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-4484(NDC:0002-3227)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Atomoxetine hydrochloride</strong> (Atomoxetine) </td>
<td class="formItem">Atomoxetine</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (opaque white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LILLY;3227;10;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-4484-3</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021411</td>
<td class="formItem">01/10/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-4484)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e0dfed21-1067-40b2-b482-210d7c971dc8</div>
<div>Set id: 6a7584b5-524d-4726-86a2-1b08e422f60e</div>
<div>Version: 2</div>
<div>Effective Time: 20140220</div>
</div>
</div>Â <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
